
Opinion|Videos|September 29, 2023
Rationale Surrounding Luspatercept as Potential First-Line Treatment Option for Patients With MDS
Author(s)Jamie L. Koprivnikar, MD
Dr Jamie L. Koprivnikar discusses the rationale surrounding luspatercept as a potential first-line treatment option for patients with myelodysplastic syndrome, and if it would have been an appropriate therapy for the patient in the presented case study.
Episodes in this series





































